Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amplify Weight Loss Drug & Treatment ETF (NY:THNR)

23.67 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 23.67
Bid (Size) 9.470 (200)
Ask (Size) 37.63 (100)
Prev. Close 23.67
Today's Range 23.67 - 23.67
52wk Range 18.56 - 27.28
Shares Outstanding 1,300
Dividend Yield 1.75%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗
Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products. 
Via Stocktwits
News headline image
Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance ↗
Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is... 
Via Stocktwits
Topics Intellectual Property

Performance

YTD
-6.9%
-6.9%
1 Month
-9.4%
-9.4%
3 Month
-9.4%
-9.4%
6 Month
+4.1%
+4.1%
1 Year
+9.1%
+9.1%

More News

Read More
News headline image
LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗
Via Stocktwits
News headline image
Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗
Via Stocktwits
Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill ↗
Via Stocktwits
The 2025 Weight-Loss Drug Gold Rush: How Eli Lilly Pulled Ahead, Novo Hit A Snag — And A Swarm Of Biotech Underdogs Are Closing In ↗
Via Stocktwits
News headline image
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs ↗
Via Benzinga
Topics ETFs
News headline image
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares ↗
Via Benzinga
Topics ETFs
News headline image
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗
Via Benzinga
News headline image
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential ↗
Via Benzinga
Topics ETFs

Frequently Asked Questions

Is Amplify Weight Loss Drug & Treatment ETF publicly traded?
Yes, Amplify Weight Loss Drug & Treatment ETF is publicly traded.
What exchange does Amplify Weight Loss Drug & Treatment ETF trade on?
Amplify Weight Loss Drug & Treatment ETF trades on the New York Stock Exchange
What is the ticker symbol for Amplify Weight Loss Drug & Treatment ETF?
The ticker symbol for Amplify Weight Loss Drug & Treatment ETF is THNR on the New York Stock Exchange
What is the current price of Amplify Weight Loss Drug & Treatment ETF?
The current price of Amplify Weight Loss Drug & Treatment ETF is 23.67
When was Amplify Weight Loss Drug & Treatment ETF last traded?
The last trade of Amplify Weight Loss Drug & Treatment ETF was at 03/26/26 08:00 PM ET
What is the market capitalization of Amplify Weight Loss Drug & Treatment ETF?
The market capitalization of Amplify Weight Loss Drug & Treatment ETF is 30.77K
How many shares of Amplify Weight Loss Drug & Treatment ETF are outstanding?
Amplify Weight Loss Drug & Treatment ETF has 31K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.